摘要
目的 探讨CD3AK和黄芪多糖 (APS)对荷瘤动物的治疗作用。方法 将黑色素瘤B1 6细胞移植到C57BL/ 6小鼠腹腔建立动物模型 ,分别用APS、CD3AK及二者联合治疗荷瘤鼠 ,检测荷瘤鼠脾NK细胞活性和脾淋巴细胞IL - 2诱生水平以及荷瘤鼠生存期。结果 单纯APS和单纯CD3AK细胞能延长荷瘤鼠的生存期 ,分别为 1 8.64± 1 .2 1天和 2 5 .34± 3 .68天 (荷瘤鼠对照组为 1 4 .67± 2 .82天 ,P <0 .0 1 ) ;二者联合应用 ,APS能显著增强CD3AK细胞的抗肿瘤作用 ,延长荷瘤鼠的生存期 ,其生存期为 35 .65± 3 .74天 (P <0 .0 0 1 )。通过对荷瘤鼠进行细胞免疫功能观察发现 ,CD3AK细胞和APS均具有抵抗荷瘤鼠NK细胞活性、IL - 2产生能力下降的作用 ;APS对CD3AK仍有显著增强效应。结论 APS是一种实用而有效的生物反应调节剂 。
Objective To investigate the efficacy of the combination of CD3AK and APS in the treatment of mice with melanoma B16. Methods The melanoma B16 cells were transplanted into the C57BL/6 mouse abdominal cavity to set up animal models. Single APS, CD3AK and their combination were given to treat mice with melanoma B16, respectively. Then the natural killer (NK) cell activity of spleen in mice with melanoma B16, the IL-2 induced levels of lymphocytes of spleen, and the survival period in mice with melanoma were evaluated, respectively. Results Both single APS and single CD3AK could prolong the survival period of the mice with melanoma, their survival periods were 18.64±1.21 days and 25.34±3.68 days, respectively, (the survival period in the control group of mice with melanoma was 14.67±2.82 days, P<0.01 ). As in the combination, APS could significantly strengthen the anti-tumor function of CD3AK and prolong the survival period of the mice with melanoma, its survival period was 35.65±3.74 days (P<0.001). The observation on the cellular immunologic function of the mice with melanoma found that both CD3AK cells and APS could resist the activity of NK cells in mice with melanoma and the decreased IL-2 production ability. APS still could strengthen the efficacy of CD3AK. Conclusions APS was a kind of applicable, effective biological reaction regulatory agent, the combination of CD3AK and APS was effective in the treatment of late-stage neoplasm.
出处
《右江民族医学院学报》
2002年第3期332-334,共3页
Journal of Youjiang Medical University for Nationalities
基金
右江民族医学院科研经费资助课题
关键词
多糖类
杀伤细胞
单克隆抗体
肿瘤
细胞免疫
免疫佐剂
小鼠
polysaccharides
killer cells
antibodies monoclonal
neoplasms
immunity, cellular
adjuvants, immunologic
mice